Log in to search using one of your social media accounts:

 

Top 5 Practice-Changing Developments in Lung Cancer in 2017 Top 5 Practice-Changing Developments in Lung Cancer in 2017

Last year was a big one for lung cancer therapy developments. Here are five of the most clinically relevant, with a brief commentary by lung cancer expert H. Jack West, MD.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Related Links:

Annals of the American Thoracic Society,Volume 15, Issue Supplement_2, Page S124-S124, April 2018.
Source: Annals of the American Thoracic Society - Category: Respiratory Medicine Authors: Source Type: research
Annals of the American Thoracic Society,Volume 15, Issue Supplement_2, Page S127-S128, April 2018.
Source: Annals of the American Thoracic Society - Category: Respiratory Medicine Authors: Source Type: research
Chloroquine inhibits cell growth in human A549 lung cancer cells by blocking autophagy and inducing mitochondrial‑mediated apoptosis. Oncol Rep. 2018 Apr 12;: Authors: Liu L, Han C, Yu H, Zhu W, Cui H, Zheng L, Zhang C, Yue L Abstract Chloroquine (CQ) has been revealed to exhibit antitumor activity in several human tumors including lung cancer as mono‑ or add‑on therapy. The antitumor effect of CQ appears to depend on the tumor type, stage and genetic context. Few studies have focused on the mechanism concerning the antitumor effect of CQ monotherapy and the cause and effect relationship amo...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Xue B, Lu QY, Massie L, Qualls C, Mao JT Abstract MiR-106b is an oncomir and a potential target for anti-cancer therapy. We hypothesize that grape seed procyanidin extract (GSE) exerts antineoplastic effects on lung cancer through modulations of miR-106b and its downstream target. We found that GSE significantly down-regulated miR-106b in a variety of lung neoplastic cells and increased cyclin-dependent kinase inhibitor 1A (CDKN1A) mRNA and protein (p21) levels. Transfection of miR-106b mimics reversed the up-regulations of CDKN1A mRNA and p21, abrogated the GSE induced anti-proliferative and anti-invasive...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Publication date: Available online 13 April 2018 Source:Respiratory Investigation Author(s): Kohei Otsubo, Isamu Okamoto, Naoki Hamada, Yoichi Nakanishi Interstitial lung disease (ILD) is a risk factor for lung cancer development and is frequently observed in patients with lung cancer. Individuals with ILD have been excluded from most prospective clinical trials of lung cancer therapies because of the risk of ILD acute exacerbation. Thus, the optimal anticancer drug treatment for such patients has yet to be established. Tyrosine kinase inhibitors are avoided for the treatment of advanced non–small cell lung cancer (...
Source: Respiratory Investigation - Category: Respiratory Medicine Source Type: research
AbstractPurpose of ReviewThe landscape of lung cancer therapy has completely shifted in the last decade. From the surge of targeted therapy to the resurrection of immunotherapy, the need for adequate lung tissue specimen is critical to evaluate tumor specimens for predictive biomarkers for both types of therapies, hence, the importance of obtaining several samples via endoscopic bronchial ultrasound performed by pulmonologists or thoracic surgeons. Moreover, these novel therapies have also been associated with respiratory side effects which will require prompt evaluation and aggressive management by pulmonologists, oncolog...
Source: Current Respiratory Care Reports - Category: Respiratory Medicine Source Type: research
First Data Presentations for CAR T Programs, Including DLL3 in Small Cell Lung Cancer and FLT3 in Acute Myeloid Leukemia Pre-Clinical Data Evaluating Half-Life Extended Anti-BCMA BiTE® Presented for First-Time New Data Include two Studies Investigating Mcl-1 Inhibitor AMG 176 THOUSAND OAKS, Calif., April 9, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Data spans Amgen's ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)-A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy. Ramucirumab, a VEGF receptor antibody, and nintedanib, an anti-angiogenic multi-tyrosine kinase inhibitor, are approved...
Source: Oncology Research and Treatment - Category: Cancer & Oncology Source Type: research
During metastasis, cancer cells require anokis resistant mechanism to survive until reach the distant secondary tissues. As anoikis sensitization may benefit for cancer therapy, this study demonstrated the pot...
Source: Journal of Biomedical Science - Category: Biomedical Science Authors: Tags: Research Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology | Lung Cancer